Predictive Factors of Response to Phase II Cardiac Rehabilitation in Heart Failure With Reduced Ejection Fraction

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-75
SponsorCentre Hospitalier de Corbie

About this trial

Exercise intolerance, measured as peak oxygen consumption (VO₂peak) during exercise in patients with heart failure with reduced ejection fraction (HFrEF). Change in VO₂peak (ΔVO₂peak), which serves as a prognostic marker for HFrEF engaged in exercise based cardiac rehabilitation program (ExCR). Responders to ExCR generally show improved cardiac function but some patients with HFrEF do not respond to ExCR. VO₂peak depends on three major components of oxygen transport: Pulmonary (lungs), circulatory (heart and vessels) and skeletal muscle (oxygen utilization) functions. These physiological responses to ExCR may be influenced by epigenetic regulation, specifically the expression of circulating microRNAs (c-miRNAs).

Linking non-invasive measurements and epigenetic markers could 1) identify which component of the oxygen transport chain is most impaired and 2) allow personalized interventions to maximize VO₂peak improvements.

The primary objective of this stidy is to assess the association between changes in VO₂peak during exercise training and circulating microRNA expression (miR-146a, miR-191, miR-23a, miR-140, miR-1, miR-21, miR-133a, miR-17-5p, miR-3200-3p).

The secondary objective is to examine the relationship between pulmonary, cardiovascular, and neuromuscular adaptations to exercise and circulating microRNA expression.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Heart failure with reduced ejection fraction < 40%

NYHA functional class ≥ II

Clinically stable for at least 6 weeks

On optimized medical therapy for at least 6 weeks

Disqualifiers

Contraindication to regular adapted physical activity

Uncontrolled arterial hypertension

Secondary respiratory disease such as emphysema or chronic obstructive pulmonary disease (COPD)

Secondary cardiovascular disease

Trial population

Heart failure patient with altered left ventricular ejection fraction

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

ΔVO₂peak

Variation in peak oxygen consumption during exercise (ΔVO₂peak = postVO₂peak - preVO₂peak), expressed as the percentage change from baseline after exercise training.

Time frame
Day 1 : baseline value of peak oxygen consumption (preVO₂peak) Day 21: post value of peak oxygen consumption (post VO₂peak)
2

circulating microRNAs

Expression of circulating microRNAs (c-miRNAs): miR-146a, miR-191, miR-23a, miR-140, miR-1, miR-21, miR-133a, miR-17-5p, miR-3200-3p

Time frame
Day 1 : baseline expression of miRNAs (pre-miRNAs) Day 21: post values of miRNAs expression (post-miRNAs)

Secondary outcomes

1

Changes in pulmonary ventilation

Changes (pre-post exercise training) in pulmonary ventilation (VE, L·min-¹).

Time frame
Day 1: pulmonary ventilation at baseline (preVE, L·min-¹) Day 21: post value of pulmonary ventilation (postVE, L·min-¹)
2

Changes in alveolar ventilation with exercise training

Changes (pre-post exercise training) in alveolar ventilation (VA, mL·min-¹)

Time frame
Day 1: alveolar ventilation at baseline (postVA, mL·min-¹) Day 21: post value of alveolar ventilation (postVA, mL·min-¹)
3

Changes in alveolar-arterial oxygen pressure difference with exercise training

Changes (pre-post exercise training) in alveolar-arterial oxygen pressure difference (PA-aO₂, mmHg)

Time frame
Day 1: baseline alveolar-arterial oxygen pressure difference value (prePA-aO₂, mmHg) Day 21: post value of alveolar-arterial oxygen pressure difference (postPA-aO₂, mmHg)
4

Changes in cardiac index with exercise training

Changes (pre-post exercise training) in cardiac index (CI, L·min-¹·m-²)

Time frame
Day 1: baseline value of cardiac index (preCI, L·min-¹·m-²) Day 21: post value of cardiac index (postCI, L·min-¹·m-²)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.